Nykode Therapeutics ASA Asset Resilience Ratio

Latest as of December 2025: 60.32%

Nykode Therapeutics ASA asset resilience ratio. Nykode Therapeutics ASA (NYKD) has an Asset Resilience Ratio of 60.32% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Nykode Therapeutics ASA to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Nkr60.29 Million
≈ $6.34 Million USD Cash + Short-term Investments

Total Assets

Nkr99.95 Million
≈ $10.52 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Nykode Therapeutics ASA (2016–2025)

Asset resilience ratio of Nykode Therapeutics ASA from 2016 to 2025. This chart shows how Nykode Therapeutics ASA's Asset Resilience Ratio has changed over time. Read NYKD current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Nykode Therapeutics ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NYKD current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr60.29 Million 60.32%
Short-term Investments Nkr0.00 0%
Total Liquid Assets Nkr60.29 Million 60.32%

Asset Resilience Insights

  • Very High Liquidity: Nykode Therapeutics ASA maintains exceptional liquid asset reserves at 60.32% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Nykode Therapeutics ASA Industry Peers by Asset Resilience Ratio

Compare Nykode Therapeutics ASA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 15.21%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
Immunovant Inc
NASDAQ:IMVT
Biotechnology 98.50%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Amicus Therapeutics Inc
NASDAQ:FOLD
Biotechnology 8.37%

Nykode Therapeutics ASA Asset Resilience Ratio by Year (2016–2025)

Nykode Therapeutics ASA asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Nykode Therapeutics ASA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 60.32% Nkr60.29 Million
≈ $6.34 Million
Nkr99.95 Million
≈ $10.52 Million
-14.49pp
2024-12-31 74.81% Nkr114.82 Million
≈ $12.08 Million
Nkr153.48 Million
≈ $16.15 Million
-2.98pp
2023-12-31 77.79% Nkr161.95 Million
≈ $17.04 Million
Nkr208.19 Million
≈ $21.91 Million
-15.15pp
2022-12-31 92.94% Nkr205.84 Million
≈ $21.66 Million
Nkr221.48 Million
≈ $23.31 Million
+88.36pp
2021-12-31 4.58% Nkr12.17 Million
≈ $1.28 Million
Nkr265.56 Million
≈ $27.94 Million
-6.26pp
2020-12-31 10.84% Nkr24.94 Million
≈ $2.62 Million
Nkr230.03 Million
≈ $24.21 Million
-54.10pp
2019-12-31 64.94% Nkr190.33 Million
≈ $20.03 Million
Nkr293.08 Million
≈ $30.84 Million
-28.71pp
2018-12-31 93.65% Nkr143.60 Million
≈ $15.11 Million
Nkr153.34 Million
≈ $16.14 Million
-2.58pp
2017-12-31 96.23% Nkr206.37 Million
≈ $21.72 Million
Nkr214.47 Million
≈ $22.57 Million
+86.31pp
2016-12-31 9.92% Nkr2.47 Million
≈ $260.24K
Nkr24.93 Million
≈ $2.62 Million
--
pp = percentage points

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology
Market Cap
$123.19 Million
Nkr1.17 Billion NOK
Market Cap Rank
#18167 Global
#158 in Norway
Share Price
Nkr2.99
Change (1 day)
+1.01%
52-Week Range
Nkr2.12 - Nkr4.99
All Time High
Nkr91.25
About

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication… Read more